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Abstract  30 
Background: Physicians in the emergency department (ED) need additional tools to stratify patients with acute 31 
heart failure (AHF) according to risk. 32 
Objective: To predict future mortality from data readily available on ED admission. 33 
Design: Prospective cohort study.  34 
Setting: 34 Spanish EDs  35 
Participants: 4867 consecutive ED patients admitted during 2009-2011 for the derivation cohort and 3229 36 
patients admitted in 2014 for the validation cohort. 37 
Measurements:  Candidate risk factors and 30-day mortality.  38 
Results: We found 13 independent risk factors in the derivation cohort and combined them to form an overall 39 
score, which we call the MEESSI-AHF (Multiple Estimation of risk based on the Emergency department Spanish 40 
Score In patients with AHF) score. This score predicted 30-day mortality with excellent discrimination (c-41 
statistic=0.836) and calibration (Hosmer-Lemeshow P = 0.99), and it provided a steep gradient in 30-day 42 
mortality across risk groups (<2% mortality for patients in the 2 lowest risk quintiles and 45% mortality in the 43 
highest risk decile). We confirmed these characteristics in the validation cohort (for example, c-44 
statistic=0.828). Multiple sensitivity analyses failed to find important amounts of confounding or bias.   45 
 Limitations: The study was confined to a single country. Participating EDs were not selected randomly. Many 46 
patients had missing data. Measuring some risk factors was subjective.  47 
Conclusion: This tool has excellent discrimination and calibration, and it was validated in patients different 48 
from the patients used to develop it. We think physicians can consider using this tool to inform clinical 49 
decisions as we conduct further studies to determine whether the tool enhances physician decisions and 50 
improves patient outcomes.  51 
Primary Funding Source: Spanish Ministry of Health, Catalonia Govern, Fundació Marató-TV3. 52 
Keywords:  acute heart failure, risk score, outcomes. 53 
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  56 
Introduction 57 
Annual hospital admissions due to acute heart failure (AHF) in Europe and the USA exceed 1 million in each 58 
region and account for most of the costs of heart failure-related care (1, 2). The emergency department (ED) 59 
has a central position in the management of AHF, since about 90% of patients with this condition attend an ED 60 
to improve their symptoms (3, 4). Once initial treatments have been administered in the ED and their effects 61 
checked, decisions are made regarding subsequent patient management: specifically does the patient need to 62 
be hospitalized or can they be discharged home with proper treatment and follow-up. As a result of a mainly 63 
subjective, empirically-driven assessment, a highly variable proportion of AHF patients is currently being 64 
directly discharged to home from ED: 16.3% in US (5), 23.9% in Spain (4), and 36.2% in Canada (6).  65 
Although decision-making in the ED is of critical importance, emergency physicians currently are not stratifying 66 
patient by risk during this process. Some biomarkers, for example, heart-specific markers like natriuretic 67 
peptides and troponin or non-specific markers like glucose or creatinine, are associated with prognosis, but 68 
cannot by themselves predict outcomes with sufficient reliability to aid decision-making (7,8). Alternatively, 69 
several AHF risk scores have been developed (9,10), but these scores have been based on hospitalized patients 70 
thus ignoring the many AHF patients, more than a third in certain countries (6), who are entirely managed in 71 
the ED and discharged home. To our knowledge, only 3 risk scores have been developed specifically for use in 72 
the ED: 2 in Canada (the Ottawa Heart Failure Risk Scale, OHFRS, and the Emergency Heart Failure Mortality 73 
Risk Grade, EHMRG) (11,12) and 1 in United States (The Improving Heart Failure Risk Stratification in the 74 
Emergency Department, STRATIFY, scale) (13). However, some were not externally validated (OHFRS, 75 
STRATIFY), some were constructed from administrative data (OHFRS, EHMRG), some excluded a substantial 76 
portion of patients (EHMRG: palliative patients excluded; OHFRS: non-consecutive sample with multiple 77 
exclusion criteria), and some were derived from databases of limited size (OHFRS: 557 patients; STRATIFY: 78 
1033 patients). Therefore, we believe there is a need for additional tools to help physicians in the ED stratify 79 
patients with acute heart failure (AHF) according to risk.   80 
Methods 81 
The Acute Heart Failure in Emergency Departments (EAHFE) Registry 82 
The EAHFE Registry collects detailed information on consecutive patients attending 34 Spanish EDs with a final 83 
diagnosis of AHF (14,15). Hospitals participate in the EAHFE Registry voluntarily, and they include university 84 
and community hospitals, EDs with high, medium or low volume of attendances (>300, 200-300, or <200/day, 85 
respectively), and hospitals from all areas of the country. Attending emergency physicians use Framingham’s 86 
clinical diagnostic criteria (16) to identify patients for the registry.  Thereafter, the diagnosis is double-checked 87 
by the principal investigator of each centre, who makes the final adjudication of AHF diagnosis based on the 88 
review of medical charts and all complementary tests done during the ED stay and any hospitalization. The 89 
diagnosis was confirmed by natriuretic peptide determinations or echocardiography (17) in the 92% of 90 
patients included in the EAHFE Registry. The only exclusion criteria to be included in the EAHFE Registry is a 91 
diagnosis of ST-elevation myocardial infarction, which occurred in approximately 3% of patients.  92 
For every patient, data on demographics, clinical history, presentation and treatments were routinely collected 93 
on specific case record forms. Interventions, treatments and patient placements (hospital admission or 94 
discharge) were entirely based on the decision-making of the attending emergency physician. Subsequent 95 
follow-up, through telephone contact and consultation of medical records, was performed between day 31 96 
and 90. The EAHFE Registry complies with the Declaration of Helsinki and was approved by the Ethical 97 
Committees of all participating centres, and all patients gave informed consent. Around 2% of patients fulfilling 98 
inclusion and exclusion criteria refused to participate. 99 
Study design 100 
During the design of the EAHFE Registry, we planned to develop a model that could stratify patients according 101 
to their risk of experiencing adverse outcomes. We wanted this model to be used as soon as possible after 102 
arrival in the ED by the first emergency physician who saw the patient using variables routinely available in 103 
most EDs. We named this model MEESSI-AHF (Multiple Estimation of risk based on the Emergency department 104 
Spanish Score In patients with AHF). 105 
When developing the model, we selected registry patients from May 2009 and November-December 2011 for 106 
the derivation cohort and patients from January-February 2014 for the validation cohort (Figure S1). We used 107 
patients in the derivation cohort to generate a 30-day mortality risk model and we used patients from the 108 
validation cohort to measure how stable the model was.  109 
Data analysis  110 
We first identified over 88 candidate predictor variables (Supplemental Table S1) that described baseline 111 
demographics, medical history and status at admission and could potentially have prognostic implications. To 112 
develop the risk score, we used logistic regression (without interaction terms) with checks for non-linearity  113 
and forward stepwise variable selection with an entry criterion of p<0.010. We used multiple imputation with 114 
chained equations (18) to produce 50 imputed data sets for estimating missing values. Once we identified a 115 
predictor, we then identified a cut-off value based on our clinical information about the predictor’s value (e.g., 116 
serum potassium) or about the linear trend (e.g., serum creatinine and systolic blood pressure). In the final 117 
model, we formed each continuous variable into ordered categories to facilitate their use in practice. We 118 
measured the model’s discrimination with the c-statistic, and we measured the model’s calibration by 119 
comparing observed- versus model-derived mortality risk with the Hosmer-Lemeshow statistic. We conducted 120 
sensitivity analyses by type of hospital (university vs community), by daily ED census (low-medium vs high 121 
volume), and for alternative models that did not include values for Barthel index, NT-proBNP, or troponin (in 122 
any combination) because they can be those more frequently be lacking in certain ED or in certain 123 
circumstances. We compared our model with  the EHMRG model (12) in a merged data set of both derivation 124 
and validation cohorts by comparing the areas under the ROC curves for 30-day mortality with the DeLong 125 
test. We used STATA software, version 13.1 (Stata Corp, College Station, TX, USA) for all analyses.  126 
Role of the funding source 127 
This study was partially supported by competitive grants from the Institute de Salud Carlos III supported with 128 
funds from Spanish Ministry of Health, (PI10/01918, PI11/01021, PI15/01019 and PI15/00773), Fundació La 129 
Marató de TV3 (20152510), and Catalonia Govern (GRC 2009/1385 and 2014/0313). The funding source had no 130 
role in the design, conduct, and analysis of this study or in the decision to submit the manuscript for 131 
publication. 132 
 133 
Results 134 
The study derivation cohort comprises 4897 consecutive patients admitted to an ED with AHF during May 2009 135 
and Nov-Dec 2011 (Figure S1). Thirty patients were excluded from analysis due to lack of follow-up, while 136 
those with censored data (48 patients with <30 days of follow-up) were included. Patients had a mean age 137 
79.7 years, 57.1% were females, comorbidities were very frequent (83.4% had hypertension, 42.2% diabetes 138 
mellitus, 39.4% dyslipidemia, 29.9% ischemic cardiomyopathy), 89.5% had New York Heart Association (NYHA) 139 
class III-IV and 56.5% had some dependency (Barthel index <100 points) at ED arrival, and 41.5% patients had  140 
LVEF below 50%, with 52.4% of them receiving beta-blockers, 62.9% angiotensin-converter enzyme inhibitor or 141 
angiotensin-II receptor blocker, and 29.1% mineralocorticoid-receptor antagonist. Patients subsequently 142 
hospitalized (75.6%) had a median length of stay of 7 days. The rest of the characteristics of the study 143 
population are presented in Table 1.  144 
Within 30 days of admission, 500 patients (10.3%) had died. From all of the candidate predictors, a logistic 145 
regression model was used with forward stepwise variable selection to identify the final 13 highly significant 146 
independent death predictors included into the MEESSI-AHF risk score. These variables are listed in Table 1 147 
ordered by their statistical strength of prediction (i.e. Barthel index at admission is the most highly significant) 148 
and each odds ratio is adjusted for all the other variables. Figure S2 displays the independent impact of each 149 
predictor on mortality risk based on the model in Table 1, and Table S2 shows comparison in key predictor 150 
variables in patient with and without missing values.  151 
For any patient, one adds together their relevant risk coefficients plus the intercept coefficient in Table 1 to 152 
determine the multivariable risk score, which is the patient’s predicted log (odds) of dying within 30 days. The 153 
distribution of this risk score for all 4867 patients is shown in Figure 1.  Also, the curve in Figure 1 relates a 154 
patient’s risk score to the probability of dying within 30-day of admission, which ranges from 0.005 to 0.898 155 
with a median of 0.051. To facilitate the calculation of any patient’s risk of dying within 30 days, we have set 156 
up a website http://bernalte.cat/calculadora/:  for a specific patient one enters the relevant 13 items and 157 
immediately their predicted % risk of dying within 30 days is provided. 158 
Figure 2 shows the cumulative mortality over 30 days for patients classified into 6 risk groups: the bottom 4 159 
quintiles and the top two deciles of the risk score’s distribution in this derivation cohort. Good discrimination 160 
of the model was achieved, with c-statistic 0.836 (95% CI 0.818 -0.853). There was a steep gradient in 30-day 161 
mortality across risk groups: with 45% mortality for the top decile of risk and around 0.7% for the bottom 162 
quintile of risk. Similar discrimination capacity was observed in either university or community hospitals, as 163 
well as in low-medium or high-volume ED (Table 2). In this derivation cohort Figure 3(a) depicts the model 164 
goodness-of-fit, comparing observed and model-predicted 30-day mortality risk across the 6 risk groups. A 165 
useful nomenclature is as follows: low risk (first and second quintiles), intermediate risk (third and fourth 166 
quintiles), high risk (next decile) and very high risk (top decile). Sensitivity and specificity of the every risk 167 
threshold for each category plotted on a ROC curve is presented in Figure S3. Reduced models lacking Barthel 168 
index, troponin or NT-proBNP (in any combination) also showed good discriminatory capacity, ranging from 169 
0.829 and 0.784 (Table S3). Accordingly, they have been incorporated in the website calculator. 170 
Finally, we used 3229 patients recruited during Jan-Feb 2014 to validate our risk score on an external 171 
population of patients, 299 (9.26%) dying within 30 days of ED admission. Five patients of the validation cohort 172 
were excluded from analysis due to lack of follow-up, while six patients with less than 30 days follow-up were 173 
included. Comparisons for key predictor variables between derivation and validation cohorts are shown in 174 
Table S4. Distribution of the MEESSI-AHF scores is presented in Figure S4. In this validation cohort, Figure 3(b) 175 
compares the observed and model-predicted mortality in six risk groups (from lowest quintile to top decile). 176 
The model fit and extent of risk discrimination is very similar to what was found in the derivation cohort. The c-177 
statistic in the validation cohort is 0.828 (95% CI 0.802-0.853), very similar to that achieved in model 178 
development. To check goodness of model fit, the Hosmer-Lemeshow test for the derivation cohort was 179 
P=0.99, and for the validation cohort P= 0.122. When compared with the previously developed risk score 180 
EHMRG intended for 7-day mortality prediction (12) using a same sample of patients of the present study, the 181 
MEESSI-AHF had superior discrimination overall (c-statistic, 0.830 vs. 0.750; P<0.001; Figure S5).  182 
 183 
Discussion 184 
The findings we present in this study are based on a large prospective population-based cohort of consecutive 185 
AHF patients admitted to 34 hospital EDs across Spain. Patients with many types of AHF were included, except 186 
for those developing AHF during an ST-elevation myocardial infarction, and all data were recorded shortly after 187 
arrival in the ED. The 13 predictors of 30-day mortality we identified should all be promptly available in routine 188 
clinical practice worldwide; and we have provided a web calculator (http://bernalte.cat/calculadora/) to 189 
make it easier for physicians to calculate the risk for a specific patient. Using such a calculator, emergency 190 
physicians will now be able to determine whether a patient is at high (or low) risk of dying within 30 days 191 
which, in turn, might allow for better patient management. Our score may be particularly useful  in the 10% of 192 
patients at very high risk for 30-day mortality (around a 45%), as well as in the 40% of patients at low risk for 193 
30-day mortality (<2%). Identification of both groups has important management implications. For a patient 194 
with very high risk, special attention has to be focused on ensuring that the patient and relatives are aware of 195 
the severity and, assuming they are appropriate, on prompt aggressive treatments with an emphasis on early 196 
admission to an intensive care unit. For a patient with low risk, attention should be focused on treatment that 197 
will lead to early discharge from the ED to home, which is consistent with a recent consensus about patients 198 
with <2% all-cause mortality as long as they are observed long enough in the ED (19).  199 
In the US, the overall incidence rate of heart failure hospitalizations has declined 29.5% between 1998 and 200 
2007 (20). We suggest that this decline could be due to better ambulatory care that avoids patient 201 
decompensation and allows proper treatment of less severe AHF episodes without hospital admission. In this 202 
sense, there is an increasing perception that more AHF patients at low risk of adverse outcomes should avoid 203 
hospitalization (4, 21), and recent consensus opinions by clinical experts advocate that approach (19,22). 204 
Specifically, one group recommends rates of 20% to 40% direct ED discharge for patients being diagnosed with 205 
AHF (depending whether the ED lacks or possesses, respectively, a specific observation area) (19). These 206 
figures match well to patients in our low risk category (40%). Avoiding hospital admission is not only a matter 207 
of health care system efficiency improvement that could save substantial costs. Hospitalization itself could 208 
imply some potential hazards: nosocomial infection, increased errors in patient with polypharmacy, acute 209 
reactive psychosis and deteriorating functional status are quite common amongst the elderly being 210 
hospitalized. AHF patients are typically of advanced age, with a median age around 80 years in most series 211 
(4,12) (median 80 years in our cohort). However, we are not aware of any  formal tools that are currently being 212 
used to aid ED risk stratification for AHF patients. Thus, some authors have argued that direct discharge of 213 
patients without objectively-based risk stratification is putting some patients at an unacceptably high risk of 214 
adverse events (6,23). This situation contrasts with improvements achieved in other high prevalent ED 215 
conditions, such as community-acquired pneumonia and acute coronary syndromes, where risk scores have 216 
been developed (24,25) and are being widely applied to discharge less severe patients who previously would 217 
have been admitted to hospital. We believe that the MEESSI-AHF risk score can provide similar help in the 218 
management of patients with AHF, especially for elderly patients who are more challenging to evaluate (15).   219 
All 13 variables we found to be predictive have been repeatedly reported as influencing the prognosis of 220 
patients with AHF (1,11-13,15,26-28). However, in our study 4 of these variables had more than 25% missing 221 
values. We adjusted for these missing values using a multiple imputation technique. Moreover, in order to 222 
match our score to what happens when real patients are in EDs, our website calculator provides a risk score 223 
even when values for Barthel index, troponin levels,  and NT-ProBNP are not available and we have shown that 224 
these risk scores perform as well as the regular risk scores (Table S4).  225 
Our model compares favourably with other risk models. For example, our model had a c-statistic of 0.836 in 226 
the derivation cohort and 0.828 in the validation cohort, which were higher than the comparable value when 227 
we calculated the EHMRG score in 2137 patients who had all the data necessary to calculate an EHMRG score. 228 
The EHMRG model focused on a shorter-term perspective (7-day mortality) (12). We feel a longer perspective 229 
(30-day mortality) provides a better framework to create a model to aid emergency physicians. Moreover, 230 
EHMRG score excluded palliative patients (who have a higher risk of adverse events), and that could limit its 231 
generalizability. Certainly, patients only receiving palliative care are not uncommon: e.g. 10.2% of our patient 232 
had a Barthel index of 0 to 20 points (indicating complete dependence) and an additional 32.8% had a Barthel 233 
index between 21 and 60 points (indicating severe dependence) and, although not directly recorded in our 234 
study, for many of them palliative care could apply. However, we have previously demonstrated that the 235 
exclusion patients for whom palliative care could potentially apply did not significantly change the 236 
discriminatory capacity of the model (only decreased from 0.741 to 0.729) (29). Our findings, in line with 237 
previous works in this field (30), affirm that the Barthel index is a key outcome predictor, adding value to 238 
previously developed risk scores. Thus, it is important to recognize that patient frailty and dependence are key 239 
aspects that should be considered in every disease impacting on an elderly population, as it comes about AHF 240 
patients. Finally, our model has been developed using data prospectively recorded using a standardised pro 241 
forma at the time of admission to the ED, instead of using retrospective extraction from administrative 242 
reports, as was done for the EHMRG model. The latter strategy could limit reliability and completeness of data. 243 
All the above-mentioned limitations, even with more extensive patient exclusion criteria and smaller sample, 244 
also apply for the OHFRS model, which obtained a c-statistic of 0.77 (11). On the other hand, although the 245 
STRATIFY score (13) was developed using data recorded prospectively, it was derived with a limited number of 246 
cases, no external validation was done, and got moderate discriminatory capacity (c-statistic: 0.68) (13). 247 
Therefore, for the first time, we offer a risk-model with robust data from a large-scale population-based study 248 
to quickly assess patient prognosis. 249 
Our study has important limitations. Some important predictors had a high number of missing values, which 250 
we have addressed with multiple imputation techniques and sensitivity analyses. There is a possibility of a 251 
“false positive” predictor entering the risk model after testing 88 candidate predictor variables, although use 252 
of p<0.01 as entry criterion has minimised this risk. Some variables, e.g. Barthel index, NYHA class, association 253 
with ACS, or low cardiac output, are partially based on subjective interpretation, but we tried to reduce this 254 
problem by providing all research centers with a dictionary for all variables and holding meetings with all 255 
researchers just before each recruitment phase in an attempt to minimize inconsistency. Additionally, the 256 
precision of our model might change in the future, especially if new treatments for heart failure were able to 257 
modify mortality, such as angiotensin II receptor blocker neprilysin inhibitors, which were not available when 258 
this study was performed. Finally, as for any study in a single country, caution should be taken in extrapolating 259 
findings internationally. Moreover, EDs were not randomly selected but were participants of the EAHFE 260 
Registry, with special interest in AHF, so it is possible results could differ when applied to other EDs. Thus, we 261 
encourage others to explore validation of our risk model in other countries/regions. Nonetheless, we believe 262 
that our model has the potential for being used widely.  263 
In conclusion, our study demonstrates that physicians can use 13 readily available items to estimate individual 264 
risk of 30-day mortality for patients with AHF who are admitted to the ED. With strong risk discrimination, 265 
good model fit and external validation, this tool is now ready for clinical use. Further study is needed to 266 
elucidate the real potential of the MEESSI-AHF risk score for enhancing physician behaviour and improving 267 
patient outcomes. We have provided user-friendly access to a way of calculating scores for specific patients 268 
(http://bernalte.cat/calculadora/). This tool has excellent discrimination and calibration, and it was validated 269 
in patients different from the patients used to develop it. We think physicians can consider using this tool to 270 
inform clinical decisions as we conduct further studies to determine whether the tool enhances physician 271 
decisions and improves patient outcomes. We believe that this tool will be especially useful for identifying 272 
individuals at lower risk for whom further hospitalization may be not required.  273 
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